Pherecydes Pharma SA
↗Romainville, France
Pherecydes Pharma SA is a French biotechnology company founded in 2006 that specializes in precision phage therapy to treat bacterial infections resistant to antibiotics. The company develops innovative bacteriophage-based therapeutics targeting three of the most resistant and dangerous bacteria: Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli. The company pioneered the concept of precision phagotherapy, which tailors individual treatments based on the sensitivity of patients' bacterial strains to specific phages, increasing the likelihood of clinical success. In June 2023, Pherecydes merged with Erytech Pharma to form Phaxiam Therapeutics, combining Pherecydes' expertise in bacteriophage therapies with Erytech's financial resources and US presence.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Phage therapy, Antimicrobial resistance (AMR)
SIZE & FINANCIALS
Employees:51-200
Founded:2006
Ownership:subsidiary
Status:merged
FUNDING
Stage:Clinical-stage biotech
Total Raised:$34.3M
Investors:Auriga Partners, Caempus, DGA France, Elaia Partners, FaDiese
STOCK
Exchange:Euronext Paris / Nasdaq
Ticker:PHXM (merged entity Phaxiam)
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Bacteriophage therapy, Phage therapy
Active Trials:3
Trial Phases:Phase 1: 2 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Phaxiam Therapeutics (merged entity)
Acquired By:Erytech Pharma (merged to form Phaxiam Therapeutics) (2023-06-23)
Key Partnerships:Erytech Pharma (merged June 2023 to form Phaxiam Therapeutics), BIOASTER - collaboration on complicated urinary tract infections, EU Horizon 2020 - funding for PhagoPROD (manufacturing and good manufacturing practices), Investigator-sponsored trials with various research institutions
COMPETITION
Position:Leader
Competitors:Adaptive Phage Therapeutics, BiomX, Eligo Bioscience, Locus Biosciences, Armata Pharmaceuticals, Intralytix, Microgen, Micreos +5 more
LEADERSHIP
Key Executives:
Guy-Charles Fanneau de La Horie - Chief Executive Officer
Thibaut du Fayet - CEO of Phaxiam Therapeutics (merged entity)
Scientific Founders:Jean-Noël Gressier (founder)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Pherecydes Pharma SA. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.